American Well Corporation (AMWL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant declines in revenue, subscription, and visit metrics, alongside reduced gross profit and margin pressure. Despite improved operating expenses and EBITDA, the lack of clear guidance on DHA renewal and AI integration impact, coupled with unclear management responses, heightens uncertainty. The Q&A section suggests optimism but lacks concrete data, and the 2026 guidance presents both headwinds and tailwinds. The absence of a market cap limits precise prediction, but overall sentiment leans negative due to financial declines and uncertainty in strategic renewals.
Key Financial Performance
Total Revenue (2025) $249.3 million, with subscription revenue representing 53% of total revenue, up from 45% in 2024. This reflects a strategic shift towards higher-quality, predictable SaaS-based revenue streams.
Net Loss and Adjusted EBITDA Loss (2025) Reduced by approximately $100 million each year-over-year, driven by disciplined cost actions and a more focused operating model.
Total Revenue (Q4 2025) $55.3 million, a 22.1% year-over-year decline. The decline was primarily due to the step down in the DHA contract, earlier churn in 2024, and reprioritization of certain business areas.
Subscription Revenue (Q4 2025) $28.8 million, down 22% year-over-year, driven by the DHA contract reduction and earlier churn in 2024.
AMG Visit Revenue (Q4 2025) $23.7 million, down 18.7% year-over-year, reflecting the sale of APC and remaining churn from 2024.
Total Platform Visits (Q4 2025) 1 million visits, down 28.4% year-over-year from 1.4 million visits in Q4 2024, consistent with portfolio changes.
Gross Profit (Q4 2025) $28.3 million, down 17.6% year-over-year, with a gross margin of 51.2%, representing a 280 basis point decline year-over-year. The margin pressure is expected to improve over time with a shift towards higher-margin SaaS offerings.
Operating Expenses (Q4 2025) $55.3 million, a 30.7% reduction year-over-year, reflecting benefits from transformation actions and cost discipline.
Adjusted EBITDA (Q4 2025) Loss of $10.3 million, a 55% improvement year-over-year from a loss of $22.8 million in Q4 2024.
Net Loss (Q4 2025) $25.2 million, a 43.5% improvement year-over-year from $30.7 million in Q4 2024.
Cash Burn (Q4 2025) Approximately $19 million, ending the year with $182 million in cash and marketable securities, and no debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Amwell Platform: Focused exclusively on offering the best tech platform in the market, enabling personalized, AI-powered care programs and integration of third-party solutions.
AI Integration: Enhanced patient experience, faster third-party integration, better clinical data utilization, and faster deployments.
Payer Segment: Executed over 15 payer contract renewals, including a 3-year renewal with Elevance and new logo wins, validating platform strategy.
Government Contracts: Renewed contracts with the Defense Health Agency, demonstrating compliance with stringent security standards.
Cost Reduction: Reduced net loss and adjusted EBITDA losses by approximately $100 million in 2025 through disciplined cost actions and a focused operating model.
Revenue Shift: Subscription revenue increased to 53% of total revenue in 2025, up from 45% in 2024, reflecting a shift to higher-quality SaaS-based revenue streams.
Divestment of Non-Core Activities: Sold APC and restructured the company to focus on core payer and government markets.
Focus on High-Quality Revenue: Shifted to high-quality, sticky revenue streams, reducing non-core activities and aligning with long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Aging Medicare Population: The rapidly aging Medicare population is increasing demand for healthcare services, which could strain resources and impact operational efficiency.
Rising Pharmacy Costs: Surging pharmacy costs, particularly in behavioral health and GLP-1 usage, are driving up overall healthcare expenses, posing financial challenges.
Clinician Shortages: Worsening clinician shortages are creating gaps in care delivery, potentially impacting service quality and patient outcomes.
Expiration of ACA Subsidies: The expiration of ACA subsidies is expected to drive member disenrollment, adversely affecting payer risk mix and financial stability.
Security Vulnerabilities: Managing multiple point solutions creates security vulnerabilities, which could lead to data breaches and operational disruptions.
Vendor Sprawl: Fragmented IT strategies and vendor sprawl lead to inefficiencies, higher integration costs, and disjointed member experiences.
Economic Pressures on Payer Margins: Rapidly compressing payer margins due to rising costs and economic pressures could impact financial performance and strategic investments.
Dependence on AI and Automation: While AI and automation offer opportunities, they also introduce risks related to implementation, governance, and potential errors in care delivery.
Revenue Decline: A 22.1% year-over-year decline in total revenue, driven by contract step-downs and churn, highlights financial vulnerabilities.
Operational Cost Pressures: Near-term margin pressures and the need for strict fiscal discipline could limit operational flexibility and growth investments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations for 2026: Amwell expects revenue in the range of $195 million to $205 million for the full year 2026. For the first quarter of 2026, revenue is projected to be between $48 million and $53 million.
AMG Visit Projections: Amwell anticipates AMG visits to range between 1.32 million and 1.37 million visits in 2026.
Adjusted EBITDA Loss: The company projects an adjusted EBITDA loss in the range of $24 million to $18 million for the full year 2026. For the first quarter, the adjusted EBITDA loss is expected to be between $7 million and $5 million.
Cash Flow Breakeven: Amwell aims to achieve positive cash flow from operations by the fourth quarter of 2026.
Market Trends and Strategic Focus: The company plans to focus on high-quality, high-margin, and sticky revenue streams, driven by AI-enhanced patient experiences, faster third-party integration, and better clinical data utilization. Amwell also aims to capitalize on the growing adoption of technology-enabled care and AI-driven efficiencies.
Operational Efficiency and Cost Discipline: Amwell will continue to implement strict fiscal discipline and cost management to support its financial goals in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:As we think about 2026, how should we think about when existing client contracts would be up for renewal? And do you have any additional color related to your government opportunities?
A:In 2025, 50 contracts were signed, most of which were renewals, securing a recurring revenue base. The number of renewals in 2026 will be significantly lower, except for the DHA renewal expected this summer. The company is optimistic about a multi-year renewal in this important market segment.
Q:What are your thoughts on some of the new AI companies entering the healthcare market and their impact on the competitive landscape?
A:The company is optimistic about AI's impact on healthcare, emphasizing its integration into clinical programs like MSK, diabetes, and blood pressure management. Amwell's role is to provide a regulated infrastructure to integrate and manage multiple AI programs. The company believes its platform is uniquely positioned to support AI adoption across its client base.
Q:Can you talk about some of the headwinds and tailwinds that could cause either an increase or risk to the 2026 guide?
A:Tailwinds include earlier adoption of the technology-enabled platform and participation in government RFIs and RFPs, with potential revenue starting in 2027. Headwinds include the DHA renewal this summer, though the company is confident about its renewal. Other material contracts are not up for renewal in 2026.
Q:Can you remind me about the DHA renewal and the potential revenue impact?
A:The company experienced a reduction in DHA revenue in 2025 due to the elimination of digital behavioral health and automated care programs. These programs had strong uptake but were cut due to cost efficiency mandates. The company is optimistic about reinstating these programs in the upcoming renewal, which would be materially significant.
Q:How do you think about 2026 as a baseline for resuming growth, and what does the long-term growth profile look like?
A:The company has streamlined its offerings into one platform, focusing on technology-enabled care. Growth is expected from increased usage across the care continuum and adding AI-driven clinical programs. The government sector and same-store growth present significant opportunities. The platform's deep integration with clients' financial and clinical systems supports long-term growth.
Q:Can you give more details on the improvement in revenue quality and the impact of divestitures?
A:The company has centralized its offerings around the Amwell Platform, divesting non-core areas like APC. The 2026 revenue and EBITDA reflect a diminishing impact from residual non-core activities. The focus on one product across all segments is expected to drive efficiency and growth.
Q:How are recent renewals informing your go-to-market approach for new opportunities, and where are you focusing efforts for net new logos?
A:Recent renewals have centered on the new Amwell Platform, which integrates deeply with clients' systems. The company is focusing on same-store growth and a large pipeline of new opportunities, particularly in the government and commercial payer segments. Health systems are also a focus but to a lesser extent.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial impact of the DHA renewal and the exact revenue contribution of reinstating the eliminated programs. Additionally, while they mentioned a large pipeline of opportunities, they did not provide concrete numbers or timelines for these potential deals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
AMG
Blue
DHA
GLP
MSK
Payers health
SaaS
Sponsors
action
activity
automation
base
benefit
consolidation
contract
cost discipline
decline
efficiency
health system
improvement loss
infrastructure
loss improvement
outcome
partner
path
payer government
refocus progress
renewal
resilience
sale APC
security
sponsor
subscription
summer
tech platform
transformation
trend
utilization
visibility
AMWL Transcript
American Well Corporation (AMWL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call lacked detailed financial information and updates on operational performance, making it difficult to gauge the company's current state. The focus on platform development and addressing customer needs is positive, but concerns about regulatory hurdles and strategic execution risks introduce uncertainties. The absence of explicit financial metrics or shareholder return plans further limits positive sentiment. Overall, the lack of critical financial details and mixed strategic signals suggest a neutral outlook.
American Well Corporation (AMWL) Q4 2025 Earnings Call Transcript
Unknown2-13
The earnings call reveals significant declines in revenue, subscription, and visit metrics, alongside reduced gross profit and margin pressure. Despite improved operating expenses and EBITDA, the lack of clear guidance on DHA renewal and AI integration impact, coupled with unclear management responses, heightens uncertainty. The Q&A section suggests optimism but lacks concrete data, and the 2026 guidance presents both headwinds and tailwinds. The absence of a market cap limits precise prediction, but overall sentiment leans negative due to financial declines and uncertainty in strategic renewals.
CAVA Group, Inc. (CAVA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture: while there are positive elements such as improved subscription revenue and cost reduction initiatives, the revised revenue guidance and negative EBITDA projections temper the outlook. The Q&A section highlights concerns about operational challenges and macroeconomic pressures, which, along with unclear management responses, suggest cautious investor sentiment. The overall sentiment is neutral, as the positive and negative factors seem to balance each other out.
American Well Corporation (AMWL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call presents a mixed but generally positive outlook. Despite a revenue guidance cut, the company shows strong cost containment and improving margins, with a significant GAAP gross margin increase. The Q&A highlights strategic wins like the Florida Blues plan, divestiture focus, and AI's role in efficiency, all suggesting positive market sentiment. The EBITDA loss improvement and cash position are reassuring, while the lack of detailed guidance on AI's financial impact is a minor concern. Overall, the strategic focus and financial health indicators suggest a positive stock reaction.
AMWL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
